↓ Skip to main content

A phase I dose-escalation study of a biosimilar trastuzumab in Chinese metastasis breast cancer patients

Overview of attention for article published in SpringerPlus, December 2015
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
12 Dimensions

Readers on

mendeley
36 Mendeley
Title
A phase I dose-escalation study of a biosimilar trastuzumab in Chinese metastasis breast cancer patients
Published in
SpringerPlus, December 2015
DOI 10.1186/s40064-015-1603-5
Pubmed ID
Authors

Xinna Zhou, Jing Yu, Wenmiao Wang, Guohong Song, Xiaoli Wang, Jun Ren, Lijun Di, Xinghe Wang

Abstract

Trastuzumab has been widely used among the breast cancer patients with human epidermal growth factor receptor 2 (HER2) overexpression. The genetically engineered trastuzumab traded as Cipterbin® was developed in China since 2003. We have disclosed the phase I clinical trial data of safety, pharmacokinetic profile (PK) in patients with metastasis breast cancer. Subjects identified as HER2 strong positive received single intravenously doses of 100, 250 or 500 mg Cipterbin® in dose-escalation manner. The safety evaluations were recorded and plasma concentration profiles for the drug were analyzed. 27 Chinese metastatic breast cancer patients were enrolled in this study. Patients in each group of different dosage were well-tolerated. The most frequently drug-related adverse events were fever (59.3 %), transaminase increased (22.2 %), chills (18.5 %) and arrhythmia (18.5 %). Only one patient with severe adverse event was observed in 250 mg group revealing brachycardia. PK profile analysis showed that sera steady concentration could be reached in dose-proportional manner, except volume of distribution (Vd) and clearance (CL), which reached peak values at 250 mg administration cohort. This genetically engineered HER2-target antibody had demonstrated the accepted safety with well-tolerated.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 36 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 36 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 8 22%
Lecturer 1 3%
Student > Doctoral Student 1 3%
Student > Bachelor 1 3%
Unspecified 1 3%
Other 4 11%
Unknown 20 56%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 4 11%
Medicine and Dentistry 4 11%
Agricultural and Biological Sciences 2 6%
Psychology 2 6%
Economics, Econometrics and Finance 1 3%
Other 3 8%
Unknown 20 56%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 December 2015.
All research outputs
#5,880,012
of 6,865,651 outputs
Outputs from SpringerPlus
#1,244
of 1,663 outputs
Outputs of similar age
#240,279
of 296,127 outputs
Outputs of similar age from SpringerPlus
#198
of 331 outputs
Altmetric has tracked 6,865,651 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,663 research outputs from this source. They receive a mean Attention Score of 3.0. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 296,127 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 331 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.